Within a few years, respiratory syncytial virus went from a disease with one niche prophylactic antibody to a field with several. Nirsevimab is now recommended for broad infant use across many markets, and in 2025 a second long-acting antibody, clesrovimab (marketed as Enflonsia, and known in Chinese-language coverage as 克莱罗韦), was approved. The dense sequence of approvals has pushed pediatric infection prevention and respiratory multiplex testing into mainstream discussion. Underneath the headlines sits a technical fact that matters for anyone who makes immunoassay reagents: every one of these antibodies targets the same metastable viral protein, the RSV fusion (F) glycoprotein, and the structural properties that make F an excellent drug target also make it a difficult antigen to raise good antibodies against.
This article defines what long-acting RSV prevention antibodies are, explains the prefusion and postfusion conformations of the F protein and the antigenic sites that drive neutralization, walks through why prefusion-specific conformational epitopes are hard to work with in antibody development, and connects all of that to respiratory co-testing and the recombinant respiratory antigen and antibody pair coverage available from Sekbio.
1. What Are RSV Prevention Monoclonal Antibodies?
A long-acting RSV monoclonal antibody is a laboratory-produced antibody administered directly to an infant to give immediate, ready-made protection against RSV for one season. It is passive immunization: unlike a vaccine, it does not prompt the recipient to build their own immune response, so protection begins within days rather than weeks and lasts only as long as the antibody circulates. All of the current products target the RSV fusion (F) glycoprotein, because F is essential for the virus to enter host cells and antibodies that block it neutralize infection.
Three antibodies define the timeline:
- Palivizumab — in use since 1998, restricted to high-risk infants, requiring monthly intramuscular doses through the RSV season. It binds antigenic site II on F.
- Nirsevimab — an extended half-life antibody carrying an Fc modification that stretches a single seasonal dose to roughly five months of coverage, recommended for a broad infant population. It binds antigenic site Ø, an epitope unique to the prefusion form of F.
- Clesrovimab — approved in 2025, also an extended half-life antibody given as a single fixed dose, binding antigenic site IV on F.
Passive Immunization vs Vaccine
A maternal RSV vaccine given in pregnancy trains the mother's immune system to produce anti-F antibodies that cross the placenta. A monoclonal antibody skips that step and delivers a single defined antibody clone directly. Both strategies converge on the same molecular target — prefusion-stabilized F — which is why the quality of an F antigen matters across vaccines, therapeutics, and diagnostics alike.
2. RSV F Protein: Prefusion vs Postfusion Conformations
The F protein is synthesized as an inactive precursor, cleaved during maturation, and assembled into a trimer that sits on the virion surface in a metastable prefusion conformation. This form is spring-loaded: when fusion is triggered, F undergoes a large, irreversible refolding into an elongated, highly stable postfusion conformation that has already done its job of merging the viral and host membranes.
Antibodies recognize F at a set of defined antigenic sites, conventionally labeled site Ø (zero) through site V. The critical point for antibody work is that sites Ø and V exist only on prefusion F, at or near the apex of the trimer, while sites I through IV are present on both conformations. Prefusion-specific epitopes elicit the most potent neutralizing antibodies, and most of the neutralizing activity in convalescent human serum is directed at them. That is the entire rationale for building modern prevention around a prefusion target.
| Antigenic Site | Present On | Neutralization Potency | Representative Antibody |
|---|---|---|---|
| Site Ø | Prefusion only | Very high | Nirsevimab |
| Site V | Prefusion only | High | Prefusion-specific research clones |
| Site II | Prefusion and postfusion | Moderate | Palivizumab |
| Site IV | Prefusion and postfusion | Moderate | Clesrovimab |
| Site I / III | Prefusion and postfusion | Low to moderate | Non-neutralizing and cross-conformational clones |
Because nirsevimab and clesrovimab bind different sites with different conformational requirements, their resistance profiles are not identical — an escape mutation at site Ø would not necessarily affect a site IV binder, and vice versa. That distinction becomes practically important once both antibodies are in widespread seasonal use.
3. Why Prefusion-F Conformational Epitopes Are Hard to Raise Antibodies Against
The prefusion conformation is metastable by design. Left to itself, an unstabilized F ectodomain spontaneously and irreversibly converts to the postfusion form during expression, purification, freeze-thaw cycles, or even passive adsorption onto a microplate well. An immunogen or screening antigen made from unstabilized F therefore drifts steadily toward postfusion, and any antibody campaign run against it selects mostly for shared-site or postfusion binders while the potent site Ø and site V clones are lost.
The structural-biology fix
The breakthrough was engineering the prefusion trimer so it cannot refold. The DS-Cav1 design introduced an interprotomer disulfide bond plus cavity-filling substitutions that lock F in the prefusion state (McLellan et al., Science, 2013). Stabilized prefusion F is now the antigen behind licensed RSV vaccines and the standard immunogen for prefusion-specific antibody discovery. A screening antigen without comparable stabilization is not fit for raising site Ø binders.
Conformational screening, not just binding
Even with a stabilized antigen, a binding readout alone is not enough. Prefusion-specific clones must be confirmed by a differential panel: parallel ELISA against prefusion and postfusion F, competition against a known site Ø antibody, and kinetic analysis by biolayer interferometry or surface plasmon resonance. Correct trimer assembly and native-like glycosylation from a mammalian expression system are prerequisites, because a monomeric or misfolded F displays the wrong surface.
"A binding assay tells you an antibody sticks to F. Only a conformational panel tells you which F it recognizes — and for RSV that distinction is the whole game."
4. From Prevention Antibodies to Respiratory Co-Testing
The wave of prevention antibodies raises the clinical value of knowing, quickly, whether a symptomatic infant actually has RSV rather than influenza or SARS-CoV-2. That is the driver behind respiratory multiplex panels: treatment and prophylaxis decisions, ward cohorting to prevent nosocomial spread, and epidemiological tracking of who is presenting despite prevention coverage.
Diagnostics and prevention antibodies use different parts of the virus:
- Antigen rapid tests target the RSV nucleoprotein (N protein), which is abundant in nasopharyngeal secretions and more than 95% conserved between the RSV-A and RSV-B subtypes — ideal for a single test line that catches both.
- The F glycoprotein is used for serology, neutralization assays, and monoclonal antibody epitope mapping, where conformational fidelity is the priority rather than abundance.
- Escape surveillance — as nirsevimab and clesrovimab uptake grows, laboratories monitoring F for site Ø and site IV mutations need prefusion-stabilized reagents and epitope-defined antibodies to run the assays.
A respiratory panel developer therefore needs a coherent reagent set spanning conserved N-protein antibody pairs for antigen detection and conformation-controlled F antigens for the neutralization and surveillance workflows sitting alongside it.
Pro Tip
When specifying an RSV rapid test antibody pair, confirm the immunogen was the nucleoprotein, not F. N-protein pairs give the abundance and RSV-A/B cross-reactivity a point-of-care test needs; F-directed antibodies belong in the serology and epitope-mapping lane.
5. Sekbio's Respiratory Antigen and Antibody Pair Coverage
Sekbio supplies recombinant respiratory pathogen antigens and matched monoclonal antibody pairs as IVD raw materials, manufactured under an ISO 13485 quality system. For RSV, the RSV nucleoprotein antibody pair (catalog S03-RSV-22 capture and S03-RSV-23 detection) is validated for lateral flow and fluorescence immunoassay development and is cross-reactive across RSV-A and RSV-B. It pairs naturally with the influenza A/B antibody pair for a combined RSV, influenza, and SARS-CoV-2 respiratory panel.
For the conformation-sensitive side of the workflow, Sekbio produces recombinant antigens in mammalian systems with native-like folding and glycosylation, and applies conformational quality control — differential ELISA against alternative conformations, SEC-HPLC for oligomeric state, and mass spectrometry for identity — before release. Custom hybridoma and recombinant clone screening can be run with a differential prefusion/postfusion panel when a project needs conformation-specific F binders rather than generic anti-F reactivity.
To review the full range, browse the online respiratory pathogen antigen and antibody pair catalog or the infectious disease application page, and request a product datasheet for the specific target and platform you are developing.
6. Frequently Asked Questions — RSV Monoclonal Antibodies and F Protein Epitopes
What is a long-acting RSV monoclonal antibody?
A long-acting RSV monoclonal antibody is a laboratory-produced antibody given directly to an infant to provide immediate, ready-made protection against respiratory syncytial virus for one RSV season. It is passive immunization, not a vaccine: the recipient does not mount their own immune response, so protection starts within days and lasts as long as the antibody circulates. Nirsevimab and clesrovimab carry engineered Fc modifications that extend their half-life so a single dose covers roughly five months, unlike the older antibody palivizumab, which required monthly injections through the season.
How is nirsevimab different from clesrovimab?
Both are extended half-life monoclonal antibodies against the RSV fusion (F) glycoprotein given as a single dose per season, but they bind different epitopes. Nirsevimab targets antigenic site Ø, an epitope that exists only on the prefusion conformation of F at the apex of the trimer. Clesrovimab targets antigenic site IV, a more membrane-proximal epitope that is present on both prefusion and postfusion F. Because the epitopes differ, the two antibodies have different escape-mutation profiles, which matters for resistance surveillance as clinical use expands.
Why is the RSV prefusion F protein so hard to work with as an antigen?
Prefusion F is metastable. It is a spring-loaded intermediate that spontaneously and irreversibly refolds into the stable postfusion form during expression, purification, freeze-thaw, or simple adsorption onto plastic. An immunogen or screening antigen made from unstabilized F therefore drifts toward postfusion over time, so immunization and panning select mostly for shared-site or postfusion binders and rarely for the potent prefusion-specific antibodies against site Ø or site V. Producing a usable prefusion antigen requires stabilizing mutations such as the DS-Cav1 design, correct trimer assembly, native-like glycosylation, and conformational quality control.
What is the difference between prefusion and postfusion RSV F?
Prefusion F is the compact, metastable conformation displayed on infectious virions before the fusion machinery is triggered. Postfusion F is the elongated, thermodynamically stable conformation adopted after the protein has driven membrane fusion. They share antigenic sites I to IV, but sites Ø and V exist only on prefusion F, and those prefusion-specific epitopes elicit the strongest neutralizing antibodies. Most neutralizing activity in human serum is directed at prefusion-specific epitopes, which is why modern RSV vaccines and prevention antibodies are built around a stabilized prefusion target.
Do RSV antigen rapid tests detect the F protein?
Generally no. Lateral flow and fluorescence RSV antigen rapid tests target the nucleoprotein (N protein), which is far more abundant in infected respiratory secretions than the surface F glycoprotein and is more than 95 percent conserved between the RSV-A and RSV-B subtypes. The F protein is used mainly for serology, neutralization assays, and monoclonal antibody epitope mapping. Antigen detection and F-directed prevention antibodies therefore rely on different antigens and different antibody requirements.
Does Sekbio supply RSV and respiratory antigens and antibody pairs?
Yes. Sekbio supplies recombinant respiratory pathogen antigens and matched monoclonal antibody pairs for RSV, influenza A and B, and other respiratory targets, validated for lateral flow and fluorescence immunoassay development under an ISO 13485 quality system. Conformation-sensitive antigens are produced in mammalian systems with differential ELISA, SEC-HPLC, and mass spectrometry conformational quality control. Custom clone screening, recombinant antigen design, and multiplex respiratory panel support are available through Sekbio's antibody development platform.
7. Summary
The rapid succession of RSV prevention antibody approvals is a structural-biology story as much as a clinical one:
- RSV prevention antibodies are passive immunization — single-clone antibodies given directly to infants, all targeting the fusion F glycoprotein.
- Nirsevimab binds prefusion-only site Ø; clesrovimab binds site IV on both conformations — different epitopes, different escape profiles.
- Prefusion F is metastable and refolds to postfusion during handling, so an unstabilized antigen selects away from the most potent neutralizing clones.
- DS-Cav1-style stabilization plus a differential prefusion/postfusion screening panel is what makes conformation-specific F antibody discovery workable.
- Antigen rapid tests use the conserved N protein, not F — diagnostics and prevention antibodies draw on different parts of the virus.
Teams building RSV and respiratory multiplex assays need a reagent set that spans both lanes: conserved N-protein antibody pairs for antigen detection and conformation-controlled antigens for serology and escape surveillance. Sekbio's recombinant respiratory antigen and antibody pair catalog, ISO 13485 manufacturing, and conformational quality control support that full workflow — browse the respiratory pathogen antibody and antigen catalog or discuss a custom target with the antibody development team.